drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00881 | DB08894 | 954 | 1,126 | [
"DDInter1554",
"DDInter1406"
] | Quinapril | Peginesatide | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Peginesatide is a synthetic peptide attached to polyethylene glycol for the treatment of anemia. The polyethylene glycol moiety helps make the drug less immunogenic and prolongs its plasma half-life. Chemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a replica of th... | Minor | 0 | [
[
[
954,
23,
1126
]
],
[
[
954,
40,
610
],
[
610,
23,
1126
]
],
[
[
954,
40,
610
],
[
610,
1,
1058
],
[
1058,
23,
1126
]
],
[
[
954,
... | [
[
[
"Quinapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Peginesatide"
]
],
[
[
"Quinapril",
"{u} (Compound) resembles {v} (Compound)",
"Enalapril"
],
[
"Enalapril",
"{u} may cause a minor inter... | Quinapril (Compound) resembles Enalapril (Compound) and Enalapril may cause a minor interaction that can limit clinical effects when taken with Peginesatide
Quinapril (Compound) resembles Enalapril (Compound) and Enalapril (Compound) resembles Moexipril (Compound) and Moexipril may cause a minor interaction that can li... |
DB01229 | DB06674 | 973 | 908 | [
"DDInter1378",
"DDInter837"
] | Paclitaxel (protein-bound) | Golimumab | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
973,
25,
908
]
],
[
[
973,
63,
1461
],
[
1461,
23,
908
]
],
[
[
973,
63,
336
],
[
336,
24,
908
]
],
[
[
973,
24,
651
],
[
651,
2... | [
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Paclitaxel may lead to a major life threatening interaction when taken with Golimumab
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Golimumab
Paclitaxel may cause a moderate... |
DB00414 | DB09129 | 590 | 625 | [
"DDInter16",
"DDInter373"
] | Acetohexamide | Chromic chloride | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Chromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN). | Moderate | 1 | [
[
[
590,
24,
625
]
],
[
[
590,
24,
127
],
[
127,
24,
625
]
],
[
[
590,
24,
1385
],
[
1385,
63,
625
]
],
[
[
590,
63,
1645
],
[
1645,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromic chloride"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
]... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Chromic chloride
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide a... |
DB00069 | DB08904 | 367 | 375 | [
"DDInter946",
"DDInter342"
] | Interferon alfacon-1 | Certolizumab pegol | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Moderate | 1 | [
[
[
367,
24,
375
]
],
[
[
367,
24,
231
],
[
231,
24,
375
]
],
[
[
367,
24,
1434
],
[
1434,
63,
375
]
],
[
[
367,
63,
491
],
[
491,
2... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Stavudine and Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken ... |
DB01098 | DB12240 | 14 | 110 | [
"DDInter1622",
"DDInter1485"
] | Rosuvastatin | Polatuzumab vedotin | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Moderate | 1 | [
[
[
14,
24,
110
]
],
[
[
14,
24,
913
],
[
913,
23,
110
]
],
[
[
14,
63,
467
],
[
467,
24,
110
]
],
[
[
14,
24,
980
],
[
980,
24,
... | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
... | Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a minor interaction that can limit clinical effects when taken with Polatuzumab vedotin
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Simvasta... |
DB01023 | DB11730 | 409 | 351 | [
"DDInter716",
"DDInter1588"
] | Felodipine | Ribociclib | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
409,
24,
351
]
],
[
[
409,
24,
283
],
[
283,
62,
351
]
],
[
[
409,
63,
1486
],
[
1486,
24,
351
]
],
[
[
409,
24,
259
],
[
259,
2... | [
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
... | Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and ... |
DB00771 | DB00808 | 262 | 1,605 | [
"DDInter397",
"DDInter916"
] | Clidinium | Indapamide | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Minor | 0 | [
[
[
262,
23,
1605
]
],
[
[
262,
62,
811
],
[
811,
1,
1605
]
],
[
[
262,
24,
1511
],
[
1511,
62,
1605
]
],
[
[
262,
63,
85
],
[
85,
2... | [
[
[
"Clidinium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Indapamide"
]
],
[
[
"Clidinium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metolazone"
],
[
"M... | Clidinium may cause a minor interaction that can limit clinical effects when taken with Metolazone and Metolazone (Compound) resembles Indapamide (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a minor interaction that can limit ... |
DB04855 | DB09098 | 540 | 98 | [
"DDInter602",
"DDInter1700"
] | Dronedarone | Somatrem | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
540,
24,
98
]
],
[
[
540,
63,
608
],
[
608,
23,
98
]
],
[
[
540,
24,
159
],
[
159,
63,
98
]
],
[
[
540,
64,
11
],
[
11,
24,
... | [
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotre... |
DB00470 | DB00557 | 530 | 252 | [
"DDInter601",
"DDInter895"
] | Dronabinol | Hydroxyzine | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Moderate | 1 | [
[
[
530,
24,
252
]
],
[
[
530,
24,
851
],
[
851,
1,
252
]
],
[
[
530,
24,
623
],
[
623,
40,
252
]
],
[
[
530,
24,
537
],
[
537,
63,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Hydroxyzine (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine (Compound) resembles Hydroxyzine (Compound... |
DB00781 | DB00877 | 1,481 | 629 | [
"DDInter1489",
"DDInter1678"
] | Polymyxin B | Sirolimus | Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. All gram-positive bacteria, fungi, and the gram... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Major | 2 | [
[
[
1481,
25,
629
]
],
[
[
1481,
21,
28921
],
[
28921,
60,
629
]
],
[
[
1481,
24,
1438
],
[
1438,
24,
629
]
],
[
[
1481,
24,
1096
],
[
109... | [
[
[
"Polymyxin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
]
],
[
[
"Polymyxin B",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Com... | Polymyxin B (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Sirolimus (Compound)
Polymyxin B may cause a moderate interaction that could exacerbate diseases when taken with Estradiol and Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Sirolimu... |
DB00945 | DB09268 | 1,479 | 1,662 | [
"DDInter20",
"DDInter1464"
] | Acetylsalicylic acid | Picosulfuric acid | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1479,
24,
1662
]
],
[
[
1479,
63,
1252
],
[
1252,
23,
1662
]
],
[
[
1479,
63,
1027
],
[
1027,
24,
1662
]
],
[
[
1479,
25,
1618
],
[
16... | [
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"... | Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Pi... |
DB11793 | DB13985 | 738 | 546 | [
"DDInter1297",
"DDInter1108"
] | Niraparib | Lutetium Lu 177 dotatate | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dot... | Moderate | 1 | [
[
[
738,
24,
546
]
],
[
[
738,
63,
66
],
[
66,
24,
546
]
],
[
[
738,
24,
270
],
[
270,
24,
546
]
],
[
[
738,
64,
1057
],
[
1057,
25,... | [
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
... | Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizum... |
DB00390 | DB00563 | 1,252 | 663 | [
"DDInter554",
"DDInter1174"
] | Digoxin | Methotrexate | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Moderate | 1 | [
[
[
1252,
24,
663
]
],
[
[
1252,
6,
13478
],
[
13478,
45,
663
]
],
[
[
1252,
18,
8569
],
[
8569,
45,
663
]
],
[
[
1252,
7,
7448
],
[
7448,... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Digoxin",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B3"
],
[
"SLCO1B3",
"{u} (Gene) is bound by {v} (Compound)",
... | Digoxin (Compound) binds SLCO1B3 (Gene) and SLCO1B3 (Gene) is bound by Methotrexate (Compound)
Digoxin (Compound) downregulates TYMS (Gene) and TYMS (Gene) is bound by Methotrexate (Compound)
Digoxin (Compound) upregulates MOK (Gene) and MOK (Gene) is upregulated by Methotrexate (Compound)
Digoxin (Compound) downregula... |
DB00213 | DB00994 | 837 | 361 | [
"DDInter1388",
"DDInter1277"
] | Pantoprazole | Neomycin | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer o... | Moderate | 1 | [
[
[
837,
24,
361
]
],
[
[
837,
21,
28722
],
[
28722,
60,
361
]
],
[
[
837,
24,
1252
],
[
1252,
23,
361
]
],
[
[
837,
24,
1132
],
[
1132,
... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
]
],
[
[
"Pantoprazole",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused b... | Pantoprazole (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Neomycin (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Neomycin
Pantoprazo... |
DB11730 | DB11943 | 351 | 255 | [
"DDInter1588",
"DDInter495"
] | Ribociclib | Delafloxacin | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Moderate | 1 | [
[
[
351,
24,
255
]
],
[
[
351,
63,
63
],
[
63,
23,
255
]
],
[
[
351,
64,
77
],
[
77,
23,
255
]
],
[
[
351,
24,
1320
],
[
1320,
63,
... | [
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
]
],
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
],
[
... | Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Teniposide may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Ribociclib may lead to a major life threatening interaction when taken with Idarubicin and Idarubicin may cause ... |
DB00047 | DB00468 | 176 | 1,424 | [
"DDInter932",
"DDInter1557"
] | Insulin glargine | Quinine | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Moderate | 1 | [
[
[
176,
24,
1424
]
],
[
[
176,
24,
1247
],
[
1247,
62,
1424
]
],
[
[
176,
24,
964
],
[
964,
23,
1424
]
],
[
[
176,
24,
480
],
[
480,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Quinine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Do... |
DB09330 | DB11952 | 985 | 800 | [
"DDInter1352",
"DDInter612"
] | Osimertinib | Duvelisib | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
985,
24,
800
]
],
[
[
985,
24,
466
],
[
466,
62,
800
]
],
[
[
985,
63,
467
],
[
467,
24,
800
]
],
[
[
985,
24,
1476
],
[
1476,
6... | [
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[... | Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Duvelisib
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Si... |
DB00563 | DB11718 | 663 | 927 | [
"DDInter1174",
"DDInter640"
] | Methotrexate | Encorafenib | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
663,
24,
927
]
],
[
[
663,
24,
1247
],
[
1247,
23,
927
]
],
[
[
663,
24,
372
],
[
372,
24,
927
]
],
[
[
663,
63,
1324
],
[
1324,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Clofar... |
DB00519 | DB01225 | 1,638 | 500 | [
"DDInter1843",
"DDInter645"
] | Trandolapril | Enoxaparin | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Moderate | 1 | [
[
[
1638,
24,
500
]
],
[
[
1638,
21,
29173
],
[
29173,
60,
500
]
],
[
[
1638,
1,
664
],
[
664,
24,
500
]
],
[
[
1638,
63,
305
],
[
305,
... | [
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxaparin"
]
],
[
[
"Trandolapril",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema peripheral"
],
[
"Oedema peripheral",
"{u} (... | Trandolapril (Compound) causes Oedema peripheral (Side Effect) and Oedema peripheral (Side Effect) is caused by Enoxaparin (Compound)
Trandolapril (Compound) resembles Perindopril (Compound) and Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin
Trandolapril may cause... |
DB00188 | DB14761 | 168 | 242 | [
"DDInter222",
"DDInter1578"
] | Bortezomib | Remdesivir | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
168,
24,
242
]
],
[
[
168,
24,
1130
],
[
1130,
24,
242
]
],
[
[
168,
25,
1377
],
[
1377,
24,
242
]
],
[
[
168,
63,
367
],
[
367,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
],
[
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Bortezomib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may ... |
DB00675 | DB01236 | 888 | 679 | [
"DDInter1744",
"DDInter1664"
] | Tamoxifen | Sevoflurane | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Moderate | 1 | [
[
[
888,
24,
679
]
],
[
[
888,
63,
1262
],
[
1262,
40,
679
]
],
[
[
888,
6,
6365
],
[
6365,
45,
679
]
],
[
[
888,
21,
29232
],
[
29232,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevoflurane"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perflutren"
],
[
... | Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Perflutren and Perflutren (Compound) resembles Sevoflurane (Compound)
Tamoxifen (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Sevoflurane (Compound)
Tamoxifen (Compound) causes Urticaria (Side Effect) and Urticaria ... |
DB00804 | DB01069 | 1,507 | 401 | [
"DDInter543",
"DDInter1533"
] | Dicyclomine | Promethazine | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1507,
24,
401
]
],
[
[
1507,
63,
146
],
[
146,
24,
401
]
],
[
[
1507,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1507,
24,
1405
],
[
1405,
... | [
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
],
... | Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and D... |
DB00397 | DB00938 | 1,466 | 455 | [
"DDInter1458",
"DDInter1635"
] | Phenylpropanolamine | Salmeterol | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
1466,
24,
455
]
],
[
[
1466,
24,
688
],
[
688,
63,
455
]
],
[
[
1466,
6,
3576
],
[
3576,
45,
455
]
],
[
[
1466,
18,
2183
],
[
2183,
... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamo... | Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Phenylpropanolamine (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Salmeterol (Compound)
Ph... |
DB00526 | DB01101 | 1,555 | 60 | [
"DDInter1355",
"DDInter285"
] | Oxaliplatin | Capecitabine | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Moderate | 1 | [
[
[
1555,
24,
60
]
],
[
[
1555,
24,
872
],
[
872,
62,
60
]
],
[
[
1555,
64,
1176
],
[
1176,
23,
60
]
],
[
[
1555,
25,
246
],
[
246,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
],
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Oxaliplatin may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin ... |
DB00685 | DB09154 | 1,299 | 1,475 | [
"DDInter1887",
"DDInter1686"
] | Trovafloxacin | Sodium citrate | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Moderate | 1 | [
[
[
1299,
24,
1475
]
],
[
[
1299,
25,
1411
],
[
1411,
23,
1475
]
],
[
[
1299,
64,
590
],
[
590,
23,
1475
]
],
[
[
1299,
63,
663
],
[
663,
... | [
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
]
],
[
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolbutamide"
],
[
... | Trovafloxacin may lead to a major life threatening interaction when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Trovafloxacin may lead to a major life threatening interaction when taken with Acetohexamide and Acetohexamide may cause... |
DB00254 | DB00532 | 964 | 208 | [
"DDInter598",
"DDInter1152"
] | Doxycycline | Mephenytoin | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Moderate | 1 | [
[
[
964,
24,
208
]
],
[
[
964,
24,
1096
],
[
1096,
62,
208
]
],
[
[
964,
63,
1560
],
[
1560,
24,
208
]
],
[
[
964,
24,
384
],
[
384,
... | [
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephenytoin"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]... | Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Mephenytoin
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Pegasp... |
DB01259 | DB14761 | 392 | 242 | [
"DDInter1024",
"DDInter1578"
] | Lapatinib | Remdesivir | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
392,
24,
242
]
],
[
[
392,
63,
1130
],
[
1130,
24,
242
]
],
[
[
392,
64,
1377
],
[
1377,
24,
242
]
],
[
[
392,
24,
129
],
[
129,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
],
[
... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Lapatinib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may ca... |
DB00938 | DB11932 | 455 | 327 | [
"DDInter1635",
"DDInter3"
] | Salmeterol | Abametapir (topical) | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Abametapir is a member of bipyridines. | Moderate | 1 | [
[
[
455,
24,
327
]
],
[
[
455,
24,
124
],
[
124,
63,
327
]
],
[
[
455,
63,
79
],
[
79,
24,
327
]
],
[
[
455,
24,
1151
],
[
1151,
24,... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Salmeterol m... |
DB00224 | DB09030 | 215 | 840 | [
"DDInter917",
"DDInter1945"
] | Indinavir | Vorapaxar | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Major | 2 | [
[
[
215,
25,
840
]
],
[
[
215,
25,
1017
],
[
1017,
63,
840
]
],
[
[
215,
25,
578
],
[
578,
24,
840
]
],
[
[
215,
23,
222
],
[
222,
2... | [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may ... | Indinavir may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Indinavir may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interac... |
DB01015 | DB11837 | 1,247 | 1,297 | [
"DDInter1724",
"DDInter1351"
] | Sulfamethoxazole | Osilodrostat | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Minor | 0 | [
[
[
1247,
23,
1297
]
],
[
[
1247,
62,
112
],
[
112,
23,
1297
]
],
[
[
1247,
23,
401
],
[
401,
24,
1297
]
],
[
[
1247,
62,
1555
],
[
1555,
... | [
[
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osilodrostat"
]
],
[
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
... | Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Prometh... |
DB00008 | DB00277 | 491 | 1,031 | [
"DDInter1407",
"DDInter1791"
] | Peginterferon alfa-2a | Theophylline | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Moderate | 1 | [
[
[
491,
24,
1031
]
],
[
[
491,
24,
1072
],
[
1072,
63,
1031
]
],
[
[
491,
24,
702
],
[
702,
24,
1031
]
],
[
[
491,
25,
1510
],
[
1510,
... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iso... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Theophylline
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00377 | DB01015 | 1,494 | 1,247 | [
"DDInter1382",
"DDInter1724"
] | Palonosetron | Sulfamethoxazole | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Minor | 0 | [
[
[
1494,
23,
1247
]
],
[
[
1494,
6,
8374
],
[
8374,
45,
1247
]
],
[
[
1494,
21,
28709
],
[
28709,
60,
1247
]
],
[
[
1494,
25,
11
],
[
11,... | [
[
[
"Palonosetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
]
],
[
[
"Palonosetron",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Com... | Palonosetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sulfamethoxazole (Compound)
Palonosetron (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Sulfamethoxazole (Compound)
Palonosetron may lead to a major life threatening interaction when taken wit... |
DB00328 | DB06441 | 831 | 936 | [
"DDInter921",
"DDInter283"
] | Indomethacin | Cangrelor | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Moderate | 1 | [
[
[
831,
24,
936
]
],
[
[
831,
24,
477
],
[
477,
24,
936
]
],
[
[
831,
40,
24
],
[
24,
24,
936
]
],
[
[
831,
63,
305
],
[
305,
24,
... | [
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cangrelor"
]
],
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[... | Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Indomethacin (Compound) resembles Tolmetin (Compound) and Tolmetin may cause a moderate interaction that could ... |
DB00206 | DB00486 | 1,245 | 1,614 | [
"DDInter1582",
"DDInter1253"
] | Reserpine | Nabilone | An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a rese... | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Moderate | 1 | [
[
[
1245,
24,
1614
]
],
[
[
1245,
24,
530
],
[
530,
1,
1614
]
],
[
[
1245,
21,
28789
],
[
28789,
60,
1614
]
],
[
[
1245,
24,
999
],
[
999,... | [
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]
],
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
... | Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Reserpine (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Nabilone (Compound)
Reserpine may cause a mode... |
DB06290 | DB12141 | 1,449 | 971 | [
"DDInter1673",
"DDInter817"
] | Simeprevir | Gilteritinib | Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, an... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
1449,
24,
971
]
],
[
[
1449,
24,
466
],
[
466,
62,
971
]
],
[
[
1449,
63,
72
],
[
72,
24,
971
]
],
[
[
1449,
25,
283
],
[
283,
6... | [
[
[
"Simeprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Simeprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
... | Simeprevir may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Simeprevir may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and E... |
DB00346 | DB00539 | 472 | 11 | [
"DDInter44",
"DDInter1837"
] | Alfuzosin | Toremifene | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Major | 2 | [
[
[
472,
25,
11
]
],
[
[
472,
24,
1376
],
[
1376,
40,
11
]
],
[
[
472,
6,
8374
],
[
8374,
45,
11
]
],
[
[
472,
18,
2852
],
[
2852,
5... | [
[
[
"Alfuzosin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenh... | Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Toremifene (Compound)
Alfuzosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Toremifene (Compound)
Alfuzosin (Compound) downregulates CCNB1 (Gene) and CCNB1 ... |
DB00446 | DB01254 | 597 | 1,213 | [
"DDInter351",
"DDInter484"
] | Chloramphenicol | Dasatinib | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
597,
24,
1213
]
],
[
[
597,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
597,
7,
3466
],
[
3466,
46,
1213
]
],
[
[
597,
18,
10375
],
[
10375,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Chloramphenicol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Co... | Chloramphenicol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Chloramphenicol (Compound) upregulates CCNA1 (Gene) and CCNA1 (Gene) is upregulated by Dasatinib (Compound)
Chloramphenicol (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Dasatinib (Compound)
... |
DB06655 | DB09128 | 5 | 1,241 | [
"DDInter1077",
"DDInter231"
] | Liraglutide | Brexpiprazole | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Moderate | 1 | [
[
[
5,
24,
1241
]
],
[
[
5,
24,
1296
],
[
1296,
63,
1241
]
],
[
[
5,
63,
1179
],
[
1179,
24,
1241
]
],
[
[
5,
24,
98
],
[
98,
24,
... | [
[
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
... | Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Insu... |
DB00557 | DB00889 | 252 | 1,133 | [
"DDInter895",
"DDInter840"
] | Hydroxyzine | Granisetron | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Moderate | 1 | [
[
[
252,
24,
1133
]
],
[
[
252,
63,
19
],
[
19,
40,
1133
]
],
[
[
252,
24,
85
],
[
85,
1,
1133
]
],
[
[
252,
6,
12523
],
[
12523,
45... | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
... | Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine (Compound) resembles Granisetron (Compound)
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine (Compound) resembles Granisetron (Compound... |
DB09048 | DB09049 | 555 | 1,135 | [
"DDInter1284",
"DDInter1261"
] | Netupitant | Naloxegol | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug i... | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Major | 2 | [
[
[
555,
25,
1135
]
],
[
[
555,
25,
1406
],
[
1406,
62,
1135
]
],
[
[
555,
63,
888
],
[
888,
23,
1135
]
],
[
[
555,
64,
1478
],
[
1478,
... | [
[
[
"Netupitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
]
],
[
[
"Netupitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
],
[
"Neratinib",
"{u} may ... | Netupitant may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Netupitant may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a minor... |
DB04868 | DB14783 | 478 | 287 | [
"DDInter1293",
"DDInter574"
] | Nilotinib | Diroximel fumarate | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
478,
24,
287
]
],
[
[
478,
64,
1101
],
[
1101,
24,
287
]
],
[
[
478,
63,
1560
],
[
1560,
24,
287
]
],
[
[
478,
25,
384
],
[
384,
... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexa... | Nilotinib may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase ... |
DB00678 | DB01225 | 240 | 500 | [
"DDInter1095",
"DDInter645"
] | Losartan | Enoxaparin | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough simila... | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Moderate | 1 | [
[
[
240,
24,
500
]
],
[
[
240,
21,
28804
],
[
28804,
60,
500
]
],
[
[
240,
1,
911
],
[
911,
63,
500
]
],
[
[
240,
40,
1414
],
[
1414,
... | [
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxaparin"
]
],
[
[
"Losartan",
"{u} (Compound) causes {v} (Side Effect)",
"Purpura"
],
[
"Purpura",
"{u} (Side Effect) is caused by {v... | Losartan (Compound) causes Purpura (Side Effect) and Purpura (Side Effect) is caused by Enoxaparin (Compound)
Losartan (Compound) resembles Azilsartan medoxomil (Compound) and Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin
Losartan (Compound) resembles Ep... |
DB06209 | DB08918 | 256 | 41 | [
"DDInter1508",
"DDInter1059"
] | Prasugrel | Levomilnacipran | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interc... | Moderate | 1 | [
[
[
256,
24,
41
]
],
[
[
256,
63,
901
],
[
901,
40,
41
]
],
[
[
256,
6,
10215
],
[
10215,
45,
41
]
],
[
[
256,
21,
28847
],
[
28847,
... | [
[
[
"Prasugrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Prasugrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
... | Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Prasugrel (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Levomilnacipran (Compound)
Prasugrel (Compound) causes Eye disorder (Side Effect)... |
DB00500 | DB11817 | 24 | 1,259 | [
"DDInter1831",
"DDInter165"
] | Tolmetin | Baricitinib | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Moderate | 1 | [
[
[
24,
24,
1259
]
],
[
[
24,
24,
1274
],
[
1274,
24,
1259
]
],
[
[
24,
1,
831
],
[
831,
24,
1259
]
],
[
[
24,
40,
1263
],
[
1263,
2... | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
... | Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Tolmetin (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a moderate interaction that ... |
DB08946 | DB09156 | 512 | 777 | [
"DDInter962",
"DDInter964"
] | Iopanoic acid | Iopromide | Iopanoic acid contains iodine and is useful as a contrast medium in cholecystography. | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can... | Moderate | 1 | [
[
[
512,
24,
777
]
],
[
[
512,
63,
772
],
[
772,
24,
777
]
],
[
[
512,
63,
772
],
[
772,
24,
1013
],
[
1013,
63,
777
]
],
[
[
512,
6... | [
[
[
"Iopanoic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopromide"
]
],
[
[
"Iopanoic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
],
... | Iopanoic acid may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Iopanoic acid may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol and C... |
DB00495 | DB00787 | 139 | 387 | [
"DDInter1961",
"DDInter25"
] | Zidovudine | Acyclovir | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, _Varicella zoster_, herpes zoster, herpes labialis, and acute herpetic keratitis[L7303,L7315,L7318,L7321,L7324,L7327]. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young a... | Minor | 0 | [
[
[
139,
23,
387
]
],
[
[
139,
6,
16560
],
[
16560,
45,
387
]
],
[
[
139,
54,
19128
],
[
19128,
15,
387
]
],
[
[
139,
18,
2049
],
[
2049,
... | [
[
[
"Zidovudine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acyclovir"
]
],
[
[
"Zidovudine",
"{u} (Compound) binds {v} (Gene)",
"SLC22A8"
],
[
"SLC22A8",
"{u} (Gene) is bound by {v} (Compound)",
... | Zidovudine (Compound) binds SLC22A8 (Gene) and SLC22A8 (Gene) is bound by Acyclovir (Compound)
Zidovudine (Compound) is included by Nucleoside Analog (Pharmacologic Class) and Nucleoside Analog (Pharmacologic Class) includes Acyclovir (Compound)
Zidovudine (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is dow... |
DB00607 | DB08816 | 1,249 | 578 | [
"DDInter1256",
"DDInter1802"
] | Nafcillin | Ticagrelor | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be u... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
1249,
24,
578
]
],
[
[
1249,
6,
8374
],
[
8374,
45,
578
]
],
[
[
1249,
21,
28810
],
[
28810,
60,
578
]
],
[
[
1249,
24,
1135
],
[
1135... | [
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Nafcillin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Nafcillin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Nafcillin (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Ticagrelor (Compound)
Nafcillin may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB01176 | DB06204 | 537 | 768 | [
"DDInter453",
"DDInter1746"
] | Cyclizine | Tapentadol | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA... | Moderate | 1 | [
[
[
537,
24,
768
]
],
[
[
537,
6,
6017
],
[
6017,
45,
768
]
],
[
[
537,
21,
28692
],
[
28692,
60,
768
]
],
[
[
537,
63,
1123
],
[
1123,
... | [
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
]
],
[
[
"Cyclizine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Cyclizine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Tapentadol (Compound)
Cyclizine (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Tapentadol (Compound)
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Propanthel... |
DB00280 | DB00515 | 494 | 589 | [
"DDInter575",
"DDInter387"
] | Disopyramide | Cisplatin | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Moderate | 1 | [
[
[
494,
24,
589
]
],
[
[
494,
6,
8803
],
[
8803,
45,
589
]
],
[
[
494,
21,
28680
],
[
28680,
60,
589
]
],
[
[
494,
63,
58
],
[
58,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
]
],
[
[
"Disopyramide",
"{u} (Compound) binds {v} (Gene)",
"SLC22A2"
],
[
"SLC22A2",
"{u} (Gene) is bound by {v} (Compou... | Disopyramide (Compound) binds SLC22A2 (Gene) and SLC22A2 (Gene) is bound by Cisplatin (Compound)
Disopyramide (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Cisplatin (Compound)
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept... |
DB00512 | DB01337 | 91 | 1,579 | [
"DDInter1916",
"DDInter1385"
] | Vancomycin | Pancuronium | Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatm... | A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release. | Moderate | 1 | [
[
[
91,
24,
1579
]
],
[
[
91,
24,
1610
],
[
1610,
1,
1579
]
],
[
[
91,
21,
28717
],
[
28717,
60,
1579
]
],
[
[
91,
63,
352
],
[
352,
... | [
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pancuronium"
]
],
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rocuronium"
],
[
... | Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Rocuronium and Rocuronium (Compound) resembles Pancuronium (Compound)
Vancomycin (Compound) causes Flushing (Side Effect) and Flushing (Side Effect) is caused by Pancuronium (Compound)
Vancomycin may cause a moderate interaction ... |
DB00912 | DB08881 | 473 | 868 | [
"DDInter1581",
"DDInter1925"
] | Repaglinide | Vemurafenib | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
473,
24,
868
]
],
[
[
473,
6,
8374
],
[
8374,
45,
868
]
],
[
[
473,
21,
28847
],
[
28847,
60,
868
]
],
[
[
473,
24,
1247
],
[
1247,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Repaglinide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Repaglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Repaglinide (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Sulfamet... |
DB08816 | DB08867 | 578 | 807 | [
"DDInter1802",
"DDInter1897"
] | Ticagrelor | Ulipristal | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocor... | Moderate | 1 | [
[
[
578,
24,
807
]
],
[
[
578,
23,
1135
],
[
1135,
62,
807
]
],
[
[
578,
63,
600
],
[
600,
23,
807
]
],
[
[
578,
64,
609
],
[
609,
2... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ulipristal"
]
],
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole... |
DB00405 | DB00996 | 128 | 1,198 | [
"DDInter517",
"DDInter791"
] | Dexbrompheniramine | Gabapentin | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures[A186277,A186143] - today it is also widely used to tr... | Moderate | 1 | [
[
[
128,
24,
1198
]
],
[
[
128,
24,
1311
],
[
1311,
63,
1198
]
],
[
[
128,
24,
530
],
[
530,
24,
1198
]
],
[
[
128,
74,
1594
],
[
1594,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gabapentin"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopram... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Gabapentin
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB01203 | DB08865 | 699 | 1,593 | [
"DDInter1255",
"DDInter448"
] | Nadolol | Crizotinib | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
699,
24,
1593
]
],
[
[
699,
6,
4973
],
[
4973,
45,
1593
]
],
[
[
699,
18,
6212
],
[
6212,
57,
1593
]
],
[
[
699,
21,
29093
],
[
29093,... | [
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Nadolol",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"... | Nadolol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Crizotinib (Compound)
Nadolol (Compound) downregulates CSRP1 (Gene) and CSRP1 (Gene) is downregulated by Crizotinib (Compound)
Nadolol (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Nadolol may cause... |
DB00208 | DB00635 | 1,018 | 1,573 | [
"DDInter1804",
"DDInter1515"
] | Ticlopidine | Prednisone | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Minor | 0 | [
[
[
1018,
23,
1573
]
],
[
[
1018,
23,
175
],
[
175,
40,
1573
]
],
[
[
1018,
23,
251
],
[
251,
1,
1573
]
],
[
[
1018,
6,
8374
],
[
8374,
... | [
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prednisone"
]
],
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triamcinolone"
],
[
... | Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Betamethasone and Betamethasone (Compound) resembles Prednisone (... |
DB00775 | DB06441 | 1,226 | 936 | [
"DDInter1818",
"DDInter283"
] | Tirofiban | Cangrelor | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Major | 2 | [
[
[
1226,
25,
936
]
],
[
[
1226,
23,
1631
],
[
1631,
62,
936
]
],
[
[
1226,
24,
97
],
[
97,
24,
936
]
],
[
[
1226,
63,
383
],
[
383,
... | [
[
[
"Tirofiban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
]
],
[
[
"Tirofiban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",
... | Tirofiban may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Cangrelor
Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin and Oxaprozin may caus... |
DB00363 | DB00405 | 695 | 128 | [
"DDInter419",
"DDInter517"
] | Clozapine | Dexbrompheniramine | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Moderate | 1 | [
[
[
695,
24,
128
]
],
[
[
695,
24,
662
],
[
662,
63,
128
]
],
[
[
695,
24,
28
],
[
28,
1,
128
]
],
[
[
695,
6,
10104
],
[
10104,
45,... | [
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],... | Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl... |
DB09129 | DB09564 | 625 | 1,296 | [
"DDInter373",
"DDInter930"
] | Chromic chloride | Insulin degludec | Chromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN). | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
625,
24,
1296
]
],
[
[
625,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
625,
24,
1385
],
[
1385,
63,
1296
]
],
[
[
625,
63,
1411
],
[
1411,
... | [
[
[
"Chromic chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Chromic chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutami... | Chromic chloride may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Chromic chloride may cause a moderate interaction that could exacerbate diseases when taken with S... |
DB00861 | DB06715 | 914 | 239 | [
"DDInter551",
"DDInter1500"
] | Diflunisal | Potassium Iodide | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear ... | Saturated solution of Potassium Iodide (SSKI) is used pharmaceutically for emergency use in patients experiencing acute symptoms of severe hyperthyroidism (also known as thyroid storm or thyrotoxic crisis). SSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyr... | Moderate | 1 | [
[
[
914,
24,
239
]
],
[
[
914,
21,
29196
],
[
29196,
60,
239
]
],
[
[
914,
24,
116
],
[
116,
63,
239
]
],
[
[
914,
74,
1274
],
[
1274,
... | [
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium Iodide"
]
],
[
[
"Diflunisal",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Eff... | Diflunisal (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Potassium Iodide (Compound)
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 and Iodide I-131 may cause a moderate interaction that could exacerbate diseases when ta... |
DB01177 | DB13879 | 77 | 1,043 | [
"DDInter904",
"DDInter824"
] | Idarubicin | Glecaprevir | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. In combination with , glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors. It demonstrates a high genetic ba... | Moderate | 1 | [
[
[
77,
24,
1043
]
],
[
[
77,
24,
971
],
[
971,
24,
1043
]
],
[
[
77,
25,
868
],
[
868,
24,
1043
]
],
[
[
77,
74,
51
],
[
51,
24,
... | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glecaprevir"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[... | Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir
Idarubicin may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may... |
DB00333 | DB06209 | 576 | 256 | [
"DDInter1166",
"DDInter1508"
] | Methadone | Prasugrel | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Moderate | 1 | [
[
[
576,
24,
256
]
],
[
[
576,
6,
10215
],
[
10215,
45,
256
]
],
[
[
576,
21,
28681
],
[
28681,
60,
256
]
],
[
[
576,
24,
752
],
[
752,
... | [
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Methadone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
... | Methadone (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Prasugrel (Compound)
Methadone (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Methadone may cause a moderate interaction that could exacerbate diseases when taken with Cimetidi... |
DB00006 | DB00063 | 942 | 366 | [
"DDInter217",
"DDInter659"
] | Bivalirudin | Eptifibatide | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Moderate | 1 | [
[
[
942,
24,
366
]
],
[
[
942,
23,
944
],
[
944,
62,
366
]
],
[
[
942,
24,
311
],
[
311,
63,
366
]
],
[
[
942,
25,
477
],
[
477,
63,... | [
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eptifibatide"
]
],
[
[
"Bivalirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
... | Bivalirudin may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Eptifibatide
Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib and Valdecox... |
DB00193 | DB00637 | 534 | 1,557 | [
"DDInter1841",
"DDInter128"
] | Tramadol | Astemizole | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Moderate | 1 | [
[
[
534,
24,
1557
]
],
[
[
534,
6,
8374
],
[
8374,
45,
1557
]
],
[
[
534,
18,
4884
],
[
4884,
57,
1557
]
],
[
[
534,
23,
112
],
[
112,
... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Astemizole"
]
],
[
[
"Tramadol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Tramadol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Astemizole (Compound)
Tramadol (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Astemizole (Compound)
Tramadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole m... |
DB00983 | DB11124 | 480 | 209 | [
"DDInter776",
"DDInter1560"
] | Formoterol | Racepinephrine | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Racepinephrine is a racemic mixture consisting of d- and l- enantiomers. Epinephrine is a non-selective α- and β-adrenergic receptor agonist. It is a bronchodilator used in the temporary relief of mild symptoms of intermittent asthma including wheezing, tightness of chest and shortness of breath. It is an active ingred... | Moderate | 1 | [
[
[
480,
24,
209
]
],
[
[
480,
23,
1042
],
[
1042,
23,
209
]
],
[
[
480,
62,
1573
],
[
1573,
23,
209
]
],
[
[
480,
24,
688
],
[
688,
... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Racepinephrine"
]
],
[
[
"Formoterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
],
... | Formoterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide and Tetracosactide may cause a minor interaction that can limit clinical effects when taken with Racepinephrine
Formoterol may cause a minor interaction that can limit clinical effects when taken with Prednisone and ... |
DB01246 | DB06603 | 820 | 39 | [
"DDInter45",
"DDInter1387"
] | Alimemazine | Panobinostat | A phenothiazine derivative that is used as an antipruritic. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
820,
25,
39
]
],
[
[
820,
62,
1247
],
[
1247,
23,
39
]
],
[
[
820,
63,
479
],
[
479,
23,
39
]
],
[
[
820,
24,
1627
],
[
1627,
63... | [
[
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Su... | Alimemazine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil... |
DB00640 | DB05812 | 1,585 | 1,374 | [
"DDInter31",
"DDInter8"
] | Adenosine | Abiraterone | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
1585,
24,
1374
]
],
[
[
1585,
21,
28661
],
[
28661,
60,
1374
]
],
[
[
1585,
63,
1494
],
[
1494,
24,
1374
]
],
[
[
1585,
24,
1133
],
[
... | [
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Adenosine",
"{u} (Compound) causes {v} (Side Effect)",
"Acute coronary syndrome"
],
[
"Acute coronary syndrome",
... | Adenosine (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Abiraterone (Compound)
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate d... |
DB00001 | DB15035 | 1,578 | 503 | [
"DDInter1037",
"DDInter1959"
] | Lepirudin | Zanubrutinib | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Major | 2 | [
[
[
1578,
25,
503
]
],
[
[
1578,
24,
222
],
[
222,
24,
503
]
],
[
[
1578,
25,
39
],
[
39,
25,
503
]
],
[
[
1578,
24,
885
],
[
885,
2... | [
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutrami... | Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Lepirudin may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may ... |
DB11057 | DB12825 | 720 | 1,375 | [
"DDInter1223",
"DDInter1032"
] | Mineral oil | Lefamulin | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
720,
24,
1375
]
],
[
[
720,
63,
870
],
[
870,
24,
1375
]
],
[
[
720,
24,
1019
],
[
1019,
24,
1375
]
],
[
[
720,
63,
1069
],
[
1069,
... | [
[
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Deflazacor... |
DB00731 | DB01191 | 1,144 | 1,039 | [
"DDInter1269",
"DDInter518"
] | Nateglinide | Dexfenfluramine | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Moderate | 1 | [
[
[
1144,
24,
1039
]
],
[
[
1144,
35,
1529
],
[
1529,
64,
1039
]
],
[
[
1144,
6,
12523
],
[
12523,
45,
1039
]
],
[
[
1144,
24,
673
],
[
67... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Nateglinide",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when ... | Nateglinide (Compound) resembles Metamfetamine (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine may lead to a major life threatening interaction when taken with Dexfenfluramine
Nateglinide (Compound) binds CYP2D6 (Gene) and CYP2D6... |
DB00312 | DB00792 | 1,023 | 832 | [
"DDInter1423",
"DDInter1878"
] | Pentobarbital | Tripelennamine | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
1023,
24,
832
]
],
[
[
1023,
24,
100
],
[
100,
63,
832
]
],
[
[
1023,
24,
649
],
[
649,
1,
832
]
],
[
[
1023,
24,
1594
],
[
1594,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
... | Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with C... |
DB01170 | DB01284 | 1,150 | 1,042 | [
"DDInter846",
"DDInter1782"
] | Guanethidine | Tetracosactide | An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem] | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Moderate | 1 | [
[
[
1150,
24,
1042
]
],
[
[
1150,
63,
1148
],
[
1148,
23,
1042
]
],
[
[
1150,
63,
1144
],
[
1144,
24,
1042
]
],
[
[
1150,
64,
1214
],
[
12... | [
[
[
"Guanethidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Guanethidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]... | Guanethidine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Guanethidine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide... |
DB08871 | DB15965 | 36 | 1,330 | [
"DDInter666",
"DDInter1270"
] | Eribulin | Naxitamab | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Moderate | 1 | [
[
[
36,
24,
1330
]
],
[
[
36,
63,
14
],
[
14,
24,
1330
]
],
[
[
36,
24,
350
],
[
350,
24,
1330
]
],
[
[
36,
64,
1487
],
[
1487,
24,
... | [
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
... | Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfil... |
DB00563 | DB01320 | 663 | 651 | [
"DDInter1174",
"DDInter783"
] | Methotrexate | Fosphenytoin | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
663,
24,
651
]
],
[
[
663,
63,
362
],
[
362,
1,
651
]
],
[
[
663,
25,
998
],
[
998,
1,
651
]
],
[
[
663,
6,
1829
],
[
1829,
45,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Methotrexate may lead to a major life threatening interaction when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Fosphenytoin (Compound)
M... |
DB00500 | DB01240 | 24 | 885 | [
"DDInter1831",
"DDInter657"
] | Tolmetin | Epoprostenol | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
24,
24,
885
]
],
[
[
24,
63,
1061
],
[
1061,
1,
885
]
],
[
[
24,
21,
28647
],
[
28647,
60,
885
]
],
[
[
24,
24,
1512
],
[
1512,
... | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
... | Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Tolmetin (Compound) causes Urinary tract infection (Side Effect) and Urinary tract infection (Side Effect) is caused by Epoprostenol (Compound)
Tolmetin may... |
DB00284 | DB01097 | 1,647 | 1,377 | [
"DDInter11",
"DDInter1033"
] | Acarbose | Leflunomide | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
1647,
25,
1377
]
],
[
[
1647,
18,
18226
],
[
18226,
57,
1377
]
],
[
[
1647,
21,
28900
],
[
28900,
60,
1377
]
],
[
[
1647,
24,
242
],
[
... | [
[
[
"Acarbose",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Acarbose",
"{u} (Compound) downregulates {v} (Gene)",
"GDF15"
],
[
"GDF15",
"{u} (Gene) is downregulated by {v} (Compound)",
... | Acarbose (Compound) downregulates GDF15 (Gene) and GDF15 (Gene) is downregulated by Leflunomide (Compound)
Acarbose (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Leflunomide (Compound)
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00095 | DB09052 | 66 | 250 | [
"DDInter623",
"DDInter220"
] | Efalizumab | Blinatumomab | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Moderate | 1 | [
[
[
66,
24,
250
]
],
[
[
66,
24,
949
],
[
949,
63,
250
]
],
[
[
66,
63,
305
],
[
305,
24,
250
]
],
[
[
66,
24,
869
],
[
869,
24,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Efalizumab... |
DB00250 | DB01118 | 10 | 33 | [
"DDInter475",
"DDInter76"
] | Dapsone | Amiodarone | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Moderate | 1 | [
[
[
10,
24,
33
]
],
[
[
10,
6,
3486
],
[
3486,
45,
33
]
],
[
[
10,
21,
29291
],
[
29291,
60,
33
]
],
[
[
10,
24,
597
],
[
597,
24,
... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Dapsone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Dapsone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Amiodarone (Compound)
Dapsone (Compound) causes Muscular weakness (Side Effect) and Muscular weakness (Side Effect) is caused by Amiodarone (Compound)
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Chlorampheni... |
DB00790 | DB09038 | 664 | 1,450 | [
"DDInter1431",
"DDInter636"
] | Perindopril | Empagliflozin | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
664,
24,
1450
]
],
[
[
664,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
664,
24,
1486
],
[
1486,
24,
1450
]
],
[
[
664,
24,
1455
],
[
1455,
... | [
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Methylpredni... |
DB05239 | DB08880 | 866 | 1,510 | [
"DDInter425",
"DDInter1771"
] | Cobimetinib | Teriflunomide | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
866,
25,
1510
]
],
[
[
866,
25,
129
],
[
129,
63,
1510
]
],
[
[
866,
24,
1033
],
[
1033,
63,
1510
]
],
[
[
866,
24,
1136
],
[
1136,
... | [
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
... | Cobimetinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may... |
DB06372 | DB11952 | 259 | 800 | [
"DDInter1594",
"DDInter612"
] | Rilonacept | Duvelisib | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
259,
24,
800
]
],
[
[
259,
24,
310
],
[
310,
24,
800
]
],
[
[
259,
63,
467
],
[
467,
24,
800
]
],
[
[
259,
24,
1476
],
[
1476,
6... | [
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simv... |
DB00938 | DB09330 | 455 | 985 | [
"DDInter1635",
"DDInter1352"
] | Salmeterol | Osimertinib | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
455,
24,
985
]
],
[
[
455,
24,
480
],
[
480,
24,
985
]
],
[
[
455,
63,
1181
],
[
1181,
24,
985
]
],
[
[
455,
24,
1032
],
[
1032,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terf... |
DB00531 | DB12015 | 450 | 1,033 | [
"DDInter456",
"DDInter53"
] | Cyclophosphamide | Alpelisib | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
450,
24,
1033
]
],
[
[
450,
24,
738
],
[
738,
24,
1033
]
],
[
[
450,
25,
1510
],
[
1510,
24,
1033
]
],
[
[
450,
63,
377
],
[
377,
... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]... | Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Cyclophosphamide may lead to a major life threatening interaction when taken with Teriflunomide and Terifluno... |
DB01033 | DB08895 | 328 | 976 | [
"DDInter1156",
"DDInter1825"
] | Mercaptopurine | Tofacitinib | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
328,
25,
976
]
],
[
[
328,
63,
1461
],
[
1461,
23,
976
]
],
[
[
328,
24,
200
],
[
200,
63,
976
]
],
[
[
328,
24,
1430
],
[
1430,
... | [
[
[
"Mercaptopurine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vi... | Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans... |
DB00790 | DB09054 | 664 | 384 | [
"DDInter1431",
"DDInter905"
] | Perindopril | Idelalisib | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
664,
24,
384
]
],
[
[
664,
63,
305
],
[
305,
24,
384
]
],
[
[
664,
24,
891
],
[
891,
24,
384
]
],
[
[
664,
1,
954
],
[
954,
24,
... | [
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia ... | Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Perindopril may cause a moderate interaction that could exacerbate diseas... |
DB00559 | DB08865 | 152 | 1,593 | [
"DDInter223",
"DDInter448"
] | Bosentan | Crizotinib | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
152,
24,
1593
]
],
[
[
152,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
152,
21,
28771
],
[
28771,
60,
1593
]
],
[
[
152,
25,
283
],
[
283,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Bosentan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Bosentan (Compound) causes Respiratory failure (Side Effect) and Respiratory failure (Side Effect) is caused by Crizotinib (Compound)
Bosentan may lead to a major life threatening interaction when taken with Fedratinib and Fedra... |
DB01155 | DB14568 | 872 | 982 | [
"DDInter813",
"DDInter1000"
] | Gemifloxacin | Ivosidenib | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
872,
25,
982
]
],
[
[
872,
62,
112
],
[
112,
23,
982
]
],
[
[
872,
63,
543
],
[
543,
24,
982
]
],
[
[
872,
24,
28
],
[
28,
24,
... | [
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Gemifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and ... |
DB00877 | DB01222 | 629 | 617 | [
"DDInter1678",
"DDInter246"
] | Sirolimus | Budesonide | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
629,
24,
617
]
],
[
[
629,
63,
251
],
[
251,
1,
617
]
],
[
[
629,
24,
1220
],
[
1220,
1,
617
]
],
[
[
629,
6,
8374
],
[
8374,
45... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Budesonide (... |
DB00668 | DB00938 | 874 | 455 | [
"DDInter652",
"DDInter1635"
] | Epinephrine | Salmeterol | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been avail... | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
874,
24,
455
]
],
[
[
874,
64,
1523
],
[
1523,
25,
455
]
],
[
[
874,
24,
688
],
[
688,
63,
455
]
],
[
[
874,
40,
11276
],
[
11276,
... | [
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Epinephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Labetalol"
],
[
"Labetalol... | Epinephrine may lead to a major life threatening interaction when taken with Labetalol and Labetalol may lead to a major life threatening interaction when taken with Salmeterol
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate inte... |
DB00604 | DB11057 | 1,425 | 720 | [
"DDInter385",
"DDInter1223"
] | Cisapride | Mineral oil | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
1425,
24,
720
]
],
[
[
1425,
25,
927
],
[
927,
63,
720
]
],
[
[
1425,
25,
1151
],
[
1151,
24,
720
]
],
[
[
1425,
64,
758
],
[
758,
... | [
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafeni... | Cisapride may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Cisapride may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause a moderate inter... |
DB00146 | DB00436 | 160 | 323 | [
"DDInter265",
"DDInter179"
] | Calcifediol | Bendroflumethiazide | The major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties. | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Moderate | 1 | [
[
[
160,
24,
323
]
],
[
[
160,
24,
1014
],
[
1014,
1,
323
]
],
[
[
160,
24,
720
],
[
720,
63,
323
]
],
[
[
160,
25,
1041
],
[
1041,
... | [
[
[
"Calcifediol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bendroflumethiazide"
]
],
[
[
"Calcifediol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
... | Calcifediol may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Bendroflumethiazide (Compound)
Calcifediol may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mineral oil may cause a moderate inter... |
DB01024 | DB01332 | 1,096 | 731 | [
"DDInter1252",
"DDInter332"
] | Mycophenolic acid | Ceftizoxime | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to b... | Moderate | 1 | [
[
[
1096,
24,
731
]
],
[
[
1096,
24,
1453
],
[
1453,
1,
731
]
],
[
[
1096,
24,
1403
],
[
1403,
40,
731
]
],
[
[
1096,
63,
1145
],
[
1145,
... | [
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ceftizoxime"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ceftriaxone"... | Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Ceftriaxone and Ceftriaxone (Compound) resembles Ceftizoxime (Compound)
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Cefepime and Cefepime (Compound) resembles Ceftizoxi... |
DB00927 | DB01041 | 1,559 | 770 | [
"DDInter712",
"DDInter1789"
] | Famotidine | Thalidomide | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
1559,
24,
770
]
],
[
[
1559,
6,
10215
],
[
10215,
45,
770
]
],
[
[
1559,
21,
28789
],
[
28789,
60,
770
]
],
[
[
1559,
24,
609
],
[
609... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Famotidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound... | Famotidine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Thalidomide (Compound)
Famotidine (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Thalidomide (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when ta... |
DB01088 | DB14357 | 714 | 944 | [
"DDInter908",
"DDInter347"
] | Iloprost | Chamomile | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Chamomile is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Minor | 0 | [
[
[
714,
23,
944
]
],
[
[
714,
24,
256
],
[
256,
23,
944
]
],
[
[
714,
63,
582
],
[
582,
23,
944
]
],
[
[
714,
25,
792
],
[
792,
23,... | [
[
[
"Iloprost",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
],
[
"Pra... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Reteplase and Reteplase may ca... |
DB00030 | DB00841 | 1,685 | 532 | [
"DDInter934",
"DDInter577"
] | Insulin human | Dobutamine | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery. | Moderate | 1 | [
[
[
1685,
24,
532
]
],
[
[
1685,
24,
817
],
[
817,
40,
532
]
],
[
[
1685,
24,
123
],
[
123,
63,
532
]
],
[
[
1685,
24,
73
],
[
73,
2... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dobutamine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
],
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Dopamine (Compound) resembles Dobutamine (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could... |
DB11581 | DB12887 | 1,456 | 1,598 | [
"DDInter1926",
"DDInter1750"
] | Venetoclax | Tazemetostat | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process,. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lym... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
1456,
24,
1598
]
],
[
[
1456,
63,
594
],
[
594,
24,
1598
]
],
[
[
1456,
24,
738
],
[
738,
24,
1598
]
],
[
[
1456,
64,
888
],
[
888,
... | [
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
... | Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Nirapar... |
DB00722 | DB06691 | 743 | 849 | [
"DDInter1079",
"DDInter1155"
] | Lisinopril | Mepyramine | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
743,
24,
849
]
],
[
[
743,
63,
1648
],
[
1648,
24,
849
]
],
[
[
743,
24,
407
],
[
407,
63,
849
]
],
[
[
743,
24,
1376
],
[
1376,
... | [
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may... |
DB00679 | DB01211 | 684 | 609 | [
"DDInter1796",
"DDInter393"
] | Thioridazine | Clarithromycin | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Major | 2 | [
[
[
684,
25,
609
]
],
[
[
684,
6,
10215
],
[
10215,
45,
609
]
],
[
[
684,
7,
8155
],
[
8155,
46,
609
]
],
[
[
684,
18,
4360
],
[
4360,
... | [
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
]
],
[
[
"Thioridazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
... | Thioridazine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Clarithromycin (Compound)
Thioridazine (Compound) upregulates ABCC5 (Gene) and ABCC5 (Gene) is upregulated by Clarithromycin (Compound)
Thioridazine (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Clarithromycin (Comp... |
DB00087 | DB01229 | 599 | 973 | [
"DDInter41",
"DDInter1378"
] | Alemtuzumab | Paclitaxel (protein-bound) | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
599,
24,
973
]
],
[
[
599,
24,
310
],
[
310,
63,
973
]
],
[
[
599,
24,
134
],
[
134,
24,
973
]
],
[
[
599,
63,
491
],
[
491,
24,... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Alemtu... |
DB01229 | DB04868 | 973 | 478 | [
"DDInter1378",
"DDInter1293"
] | Paclitaxel (protein-bound) | Nilotinib | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
973,
24,
478
]
],
[
[
973,
24,
1468
],
[
1468,
63,
478
]
],
[
[
973,
6,
6017
],
[
6017,
45,
478
]
],
[
[
973,
7,
14972
],
[
14972,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Paclitaxel (Co... |
DB00396 | DB13928 | 989 | 1,385 | [
"DDInter1529",
"DDInter1660"
] | Progesterone | Semaglutide | Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss. Progesterone is used in var... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
989,
24,
1385
]
],
[
[
989,
1,
891
],
[
891,
24,
1385
]
],
[
[
989,
24,
1476
],
[
1476,
24,
1385
]
],
[
[
989,
63,
1685
],
[
1685,
... | [
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Progesterone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause ... | Progesterone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction t... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.